Literature DB >> 24463503

Antitumor activities of an oncolytic adenovirus equipped with a double siRNA targeting Ki67 and hTERT in renal cancer cells.

Lin Fang1, Qian Cheng1, Wang Li2, Junjie Liu2, Liantao Li1, Kai Xu3, Junnian Zheng4.   

Abstract

RNA interference has been proven to be a powerful tool for gene knockdown. Our previous study demonstrated that a Ki67 shRNA carried by an adenovirus reduced Ki67 expression. In this study, we constructed novel oncolytic adenoviruses in which the Ki67 core promoter drove expression of the E1A gene. These adenoviruses were equipped with either a Ki67 small interfering RNA (siRNA), a human telomerase reverse transcriptase (hTERT) siRNA or a double siRNA targeting Ki67 and hTERT. We identified the antitumor activities of oncolytic adenoviruses in 3 renal cancer cell lines, human normal renal tube cell HK-2 and also in nude mice bearing KETR-3-xenografted tumors. Our results showed that these oncolytic adenoviruses, especially Ki67-ZXC2-double siRNA, could effectively induce silencing of the Ki67 and hTERT genes, allow efficient viral replication and induce significant apoptosis of renal cancer cells in vitro and in nude mice. We concluded that a dual siRNA mediated by oncolytic virotherapy could be an effective strategy for cancer gene therapy.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Human telomerase reverse transcriptase; Ki67; RNA interference; Renal cell carcinoma (RCC)

Mesh:

Substances:

Year:  2014        PMID: 24463503     DOI: 10.1016/j.virusres.2013.12.021

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  8 in total

1.  Efficacy of a novel double-controlled oncolytic adenovirus driven by the Ki67 core promoter and armed with IL-15 against glioblastoma cells.

Authors:  Qing Zhang; Junwen Zhang; Yifu Tian; Guidong Zhu; Sisi Liu; Fusheng Liu
Journal:  Cell Biosci       Date:  2020-10-27       Impact factor: 7.133

Review 2.  Ki67 targeted strategies for cancer therapy.

Authors:  C Yang; J Zhang; M Ding; K Xu; L Li; L Mao; J Zheng
Journal:  Clin Transl Oncol       Date:  2017-10-20       Impact factor: 3.340

3.  Targeting Human Telomerase Reverse Transcriptase by a Simple siRNA Expression Cassette in HepG2 Cells.

Authors:  Hui Xu; Xia Gong; Hui Hui Zhang; Qin Zhang; Dandan Zhao; Jian Xiong Peng
Journal:  Hepat Mon       Date:  2015-03-31       Impact factor: 0.660

4.  Recombinant Vaccinia Viruses Coding Transgenes of Apoptosis-Inducing Proteins Enhance Apoptosis But Not Immunogenicity of Infected Tumor Cells.

Authors:  Olga Koval; Galina Kochneva; Anastasiya Tkachenko; Olga Troitskaya; Galina Sivolobova; Antonina Grazhdantseva; Anna Nushtaeva; Elena Kuligina; Vladimir Richter
Journal:  Biomed Res Int       Date:  2017-08-30       Impact factor: 3.411

Review 5.  shRNA-armed conditionally replicative adenoviruses: a promising approach for cancer therapy.

Authors:  Jie Zhang; Meng Ding; Kai Xu; Lijun Mao; Junian Zheng
Journal:  Oncotarget       Date:  2016-05-17

Review 6.  Strategies to Develop Potent Oncolytic Viruses and Enhance Their Therapeutic Efficacy.

Authors:  Omeed Moaven; Christopher W Mangieri; John A Stauffer; Panos Z Anastasiadis; Mitesh J Borad
Journal:  JCO Precis Oncol       Date:  2021-04-27

Review 7.  Targeting Tumor-Associated Antigen: A Promising CAR-T Therapeutic Strategy for Glioblastoma Treatment.

Authors:  Guidong Zhu; Qing Zhang; Junwen Zhang; Fusheng Liu
Journal:  Front Pharmacol       Date:  2021-06-24       Impact factor: 5.810

Review 8.  Chemotherapy and Oncolytic Virotherapy: Advanced Tactics in the War against Cancer.

Authors:  Andrew Nguyen; Louisa Ho; Yonghong Wan
Journal:  Front Oncol       Date:  2014-06-11       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.